Radiotherapy for human T-cell leukemia virus type 1-associated adult T-cell leukemia/lymphoma

Area of Science:

• Oncology
• Radiation Oncology
• Hematology

Background:

• Adult T-cell lymphoma/leukemia (ATL) is a rare and aggressive T-cell neoplasm.
• Limited research exists on the efficacy of radiotherapy (RT) for ATL.
• There is a need to evaluate RT's role in managing ATL local lesions.

Purpose of the Study:

• To clarify the efficacy and safety of radiotherapy (RT) for Adult T-cell lymphoma/leukemia (ATL).
• To assess response rates, local recurrence, and toxicity of RT in ATL patients.

Main Methods:

• Retrospective review of 90 RT courses in 19 ATL patients (2008-2023).
• Treatment of 90 lesions (72 cutaneous, 10 extranodal, 8 nodal) with a mean dose of 39.1 Gy.
• Analysis of response rates, local recurrence, survival, and toxicity.

Main Results:

• A 92% combined complete and partial response rate was observed.
• Local recurrence was absent in 98.9% of RT courses after a median follow-up of 47.5 months.
• Median survival time was 918 days with no reported acute grade ≥3 or late toxicity.

Conclusions:

• Radiotherapy (RT) is an effective and safe treatment modality for local lesions in Adult T-cell lymphoma/leukemia (ATL).
• RT demonstrates high efficacy with a favorable safety profile in managing ATL.
• Further investigation into RT's role in ATL treatment is warranted.